IDXG INTERPACE BIOSCIENCES, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$1.67

Period return

+0.32 (+23.70%)

Volume

15.5K

2026-06-05O $1.71 H $1.71 L $1.58 C $1.67MA5 $1.74MA20 $1.81MA60 $1.9MA120 $1.72

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2021. 11. 17.MediumHOLD5 years ago
HC Wainwright & Co.: Neutral
US analyst rating / recommendation change.
2021. 04. 09.LowBUY5 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2021. 01. 25.LowBUY5 years ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Sector: Healthcare
Industry: Diagnostics & Research
HQ: Parsippany, NJ, United States
Fiscal year end: —
Employees: 102
IPO date: —

View details →

2020. 10. 22.LowBUY6 years ago

HC Wainwright & Co.: Buy